Transcriptional analysis of doxorubicin-induced cardiotoxicity

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 290, Issue 3, 2006, Pages

  Yi, Xiaoming ^a   Bekeredjian, Raffi ^a   DeFilippis, Nicholas J ^a   Siddiquee, Zakir ^a   Fernandez, Eduardo ^a   Shohet, Ralph V ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF HAWAII   (United States)

Author keywords

Adriamycin; Dilated cardiomyopathy; Microarray

Indexed keywords

COMPLEMENTARY DNA; DOXORUBICIN; TRANSCRIPTION FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CARDIOTOXICITY; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; DNA MICROARRAY; DOSE RESPONSE; DRUG EXPOSURE; ECHOCARDIOGRAPHY; GENE CONTROL; GENE IDENTIFICATION; HEART LEFT VENTRICLE FUNCTION; HISTOPATHOLOGY; MALE; MOUSE; NONHUMAN; OXIDATION; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSCRIPTION REGULATION; ANIMAL; C57BL MOUSE; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; DRUG EFFECT; HEART; HEART MUSCLE; METABOLISM; PATHOLOGY;

ANIMALS; CARDIOMYOPATHY, DILATED; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; HEART; MALE; MICE; MICE, INBRED C57BL; MYOCARDIUM; TRANSCRIPTION FACTORS; VENTRICULAR DYSFUNCTION, LEFT;

EID: 33645738498     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00832.2005     Document Type: Article

References (38)

1. Arai A, Spencer JA, and Olson EN. STARS, a striated muscle activator of Rho signaling and serum response factor-dependent transcription. J Biol Chem 277: 24453-24459, 2002.
2. Arola OJ, Saraste A, Pulkki K, Kallajoki M, Parvinen M, and Voipio-Pulkki LM Acute doxorubicin cardiotoxicity involves cardiomyocyte apoptosis. Cancer Res 60: 1789-1792, 2000.
3. Bjarnason R, Wickelgren R, Hermansson M, Hammarqvist F, Carlsson B, and Carlsson LM. Growth hormone treatment prevents the decrease in insulin-like growth factor I gene expression in patients undergoing abdominal surgery. J Clin Endocrinol Metab 83: 1566-1572, 1998.
4. Chow CK, Yen HC, Ibrahim W, and St Clair DK. Manganese superoxide dismutase transgenic mice: characteristics and implications. Methods Enzymol 353: 398-409, 2002.
5. Cortes U, Moyret-Lalle C, Falette N, Duriez C, Ghissassi FE, Barnas C, Morel AP, Hainaut P, Magaud JP, and Puisieux A. BTG gene expression in the p53-dependent and -independent cellular response to DNA damage. Mol Carcinog 27: 57-64, 2000.
6. Danesi R, Fogli S, Gennari A, Conte P, and Del Tacca M. Pharmacokinetic-pharmacodynamic relationships of the anthracycline anticancer drugs. Clin Pharmacokinet 41: 431-444, 2002.
7. DeAtley SM, Aksenov MY, Aksenova MV, Harris B, Hadley R, Cole Harper P, Carney JM, and Butterfield DA. Antioxidants protect against reactive oxygen species associated with adriamycin-treated cardiomyocytes. Cancer Lett 136: 41-46, 1999.
8. Doroshow JH. Effect of anthracycline antibiotics on oxygen radical formation in rat heart. Cancer Res 43: 460-472, 1983.
9. Fisher DE. Apoptosis in cancer therapy: crossing the threshold. Cell 78: 539-542, 1994.
10. Franco F, Dubois SK, Peshock RM, and Shohet RV. Magnetic resonance imaging accurately estimates LV mass in a transgenic mouse model of cardiac hypertrophy. Am J Physiol Heart Circ Physiol 274: H679-H683, 1998.
11. Hardie DG. Metabolic control: a new solution to an old problem. Curr Biol 10: R757-R759, 2000.
12. Hardie DG, Salt IP, Hawley SA, and Davies SP. AMP-activated protein kinase: an ultrasensitive system for monitoring cellular energy charge. Biochem J 338: 717-722, 1999.
13. Ishiguro H, Tsunoda T, Tanaka T, Fujii Y, Nakamura Y, and Furukawa Y. Identification of AXUD1, a novel human gene induced by AXIN1 and its reduced expression in human carcinomas of the lung, liver, colon and kidney. Oncogene 20: 5062-5066, 2001.
14. Kalyanaraman B, Joseph J, Kalivendi S, Wang S, Konorev E, and Kotamraju S. Doxorubicin-induced apoptosis: implications in cardiotoxicity. Mol Cell Biochem 234-235: 119-124, 2002.
15. Kang YJ, Chen Y, Yu A, Voss-McCowan M, and Epstein PN. Overexpression of metallothionein in the heart of transgenic mice suppresses doxorubicin cardiotoxicity. J Clin Invest 100: 1501-1506, 1997.
16. Kang YJ, Zhou ZX, Wang GW, Buridi A, and Klein JB. Suppression by metallothionein of doxorubicin-induced cardiomyocyte apoptosis through inhibition of p38 mitogen-activated protein kinases. J Biol Chem 275: 13690-13698, 2000.
17. Kanter PM and Schwartz HS. Adriamycin-induced DNA damage in human leukemia cells. Leuk Res 3: 277-283, 1979.
18. Kumar D, Kirshenbaum LA, Li T, Danelisen I, and Singal PK. Apoptosis in adriamycin cardiomyopathy and its modulation by probucol. Antioxid Redox Signal 3: 135-145, 2001.
19. Lebrecht D, Setzer B, Ketelsen UP, Haberstroh J, and Walker UA. Time-dependent and tissue-specific accumulation of mtDNA and respiratory chain defects in chronic doxorubicin cardiomyopathy. Circulation 108: 2423-2429, 2003.
20. Lee YC and Byfield JE. Induction of DNA degradation in vivo by adriamycin. J Natl Cancer Inst 57: 221-224, 1976.
21. Meinardi MT, van der Graaf WT, van Veldhuisen DJ, Gietema JA, de Vries EG, and Sleijfer DT. Detection of anthracycline-induced cardiotoxicity. Cancer Treat Rev 25: 237-247, 1999.
22. Mimnaugh EG, Trush MA, Bhatnagar M, and Gram TE. Enhancement of reactive oxygen-dependent mitochondrial membrane lipid peroxidation by the anticancer drug adriamycin. Biochem Pharmacol 34: 847-856, 1985.
23. Myers CE, McGuire WP, Liss RH, Ifrim I, Grotzinger K, and Young RC. Adriamycin: the role of lipid peroxidation in cardiac toxicity and tumor response. Science 197: 165-167, 1977.
24. Nakamura T, Ueda Y, Juan Y, Katsuda S, Takahashi H, and Koh E. Fas-mediated apoptosis in adriamycin-induced cardiomyopathy in rats: in vivo study. Circulation 102: 572-578, 2000.
25. Narula J, Haider N, Virmani R, DiSalvo TG, Kolodgie FD, Hajjar RJ, Schmidt U, Semigran MJ, Dec GW, and Khaw BA. Apoptosis in myocytes in end-stage heart failure. N Engl J Med 335: 1182-1189, 1996.
26. Ogura R, Sugiyama M, Haramaki N, and Hidaka T. Electron spin resonance studies on the mechanism of adriamycin-induced heart mitochondrial damages. Cancer Res 51: 3555-3558, 1991.
27. Olson RD and Mushlin PS. Doxorubicin cardiotoxicity: analysis of prevailing hypotheses. FASEB J 4: 3076-3086, 1990.
28. Powis G. Free radical formation by antitumor quinones. Free Radic Biol Med 6: 63-101, 1989.
29. Roth DM, Swaney JS, Dalton ND, Gilpin EA, and Ross J Jr. Impact of anesthesia on cardiac function during echocardiography in mice. Am J Physiol Heart Circ Physiol 282: H2134-H2140, 2002.
30. Sahn DJ, DeMaria A, Kisslo J, and Weyman A. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 58: 1072-1083, 1978.
31. Shehan DC and Hrapchak BB. Theory and Practice of Histotechnology. Columbus, OH: Battelle, 1980.
32. Singal PK, Deally CM, and Weinberg LE. Subcellular effects of adriamycin in the heart: a concise review. J Mol Cell Cardiol 19: 817-828, 1987.
33. Singal PK and Iliskovic N. Doxorubicin-induced cardiomyopathy. N Engl J Med 339: 900-905, 1998.
34. Thellin O, Zorzi W, Lakaye B, De Borman B, Coumans B, Hennen G, Grisar T, Igout A, and Heinen E. Housekeeping genes as internal standards: use and limits. J Biotechnol 75: 291-295, 1999.
35. Tirone F. The gene PC3(TIS21/BTG2), prototype member of the PC3/ BTG/TOB family: regulator in control of cell growth, differentiation, and DNA repair? J Cell Physiol 187: 155-165, 2001.
36. Woods AE and Ellis RC. Laboratory Histopathology, A Complete Reference. Edinburgh, UK: Churchill-Livingston, 1996.
37. Yen HC, Oberley TD, Vichitbandha S, Ho YS, and St Clair DK. The protective role of manganese superoxide dismutase against adriamycin-induced acute cardiac toxicity in transgenic mice. J Clin Invest 98: 1253-1260, 1996.
38. Zhao XS, Gallardo TD, Lin L, Schageman JJ, and Shohet RV. Transcriptional mapping and genomic analysis of the cardiac atria and ventricles. Physiol Genomics 12: 53-60, 2002.